Public Policy Resources

Leading health care companies and organizations representing patients, providers, laboratories and diagnostic manufacturers called on Senate and House leaders to advance legislation that would reform and modernize the process for bringing innovative diagnostics and clinical laboratory tests to market.

The objective of cancer research is to generate new knowledge that can be used to improve survival and quality of life for patients with cancer. Clinical trials are the key step in advancing potential new cancer treatments from the research setting to the cancer care clinic, and patient participation in trials is crucial to this success.

ACS CAN supports the coverage of FDA-approved NGS panels, and also supports the coverage of panels used as part of NCI clinical trials.  CMS is encouraged to reconsider limitations on patient eligibility and is urged to create clear and achievable requirments for evidence development. 

Expanded access inovolves accessing unapproved therapies outside of clinical trials.  This process has been in existience since the late 1980s, and currently there have been calls to change the process.

Molecular tests are critical to safe, effective care for cancer patients, yet the oversight system for laboratory developed tests is in need of updating.  This letter, co-signed by 33 organizations, request that Congress act to ensure appropriate diagnostic oversight. 

This report examines the drug development landscape for childhood cancer, identifying scientific, logistical, economic and ethical challenges that are unique to pediatric cancer drug development. 

Immunotherapy is a growing area of cancer drug development, and this educational brochure explains in lay language how immunotherapies for cancer work.

This letter provides feedback on FDA's proposal to extend oversight to laboratory developed tests (LDTs).  The letter expressed ACS CAN's general support for this change.

This joint ACS/ ACS CAN letter provided feedback to proposed changes in the "Common Rule," which outlines the ethical requirements for conducting federally funded research with humans.